Moleculin to Host Virtual AML Clinical Day with Dr. Martin S. Tallman on May 7, 2024

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, recently announced plans to host a virtual event focusing on acute myeloid leukemia (AML) and its lead drug candidate, Annamycin. Scheduled for Tuesday, May 7, 2024, at 11:00 AM ET, the AML Clinical Day will feature insights from Moleculin’s Chairman and CEO, Walter Klemp, and Senior Chief Medical Officer, Dr. Paul Waymack. They will be joined by Dr. Martin Tallman, an esteemed clinical investigator with significant contributions to leukemia research.

Dr. Tallman, currently associated with the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, has an impressive track record in leukemia treatment and research. He has held prestigious positions such as the chief of the Leukemia Service at Memorial Sloan Kettering Cancer Center and Professor of Medicine at Weill Cornell Medical College. His expertise extends to leadership roles, including presidency of the American Society of Hematology in 2021 and chairmanship of the Eastern Cooperative Oncology Group’s Leukemia Committee for 16 years.

The virtual event aims to provide a comprehensive overview of Annamycin, emphasizing its potential to meet the critical needs in AML treatment. Annamycin is designed as a next-generation anthracycline to overcome multidrug resistance mechanisms with minimal cardiotoxicity. The Moleculin team and Dr. Tallman will also discuss the current treatment landscape for AML and how Annamycin could offer significant therapeutic advantages. Additionally, they will share the clinical data collected so far, aiming to illustrate the drug's potential efficacy.

Moleculin is advancing Annamycin toward a pivotal AML study anticipated to commence in 2024, potentially qualifying for accelerated approval. This progress is part of the company's broader strategy to develop treatments for challenging tumors and viruses. Beyond Annamycin, Moleculin’s pipeline includes WP1066, an Immune/Transcription Modulator targeting brain tumors and other cancers, and WP1220, aimed at treating cutaneous T-cell lymphoma. The company is also developing WP1122, an antimetabolite with potential applications in both viral infections and cancer treatment.

The virtual roundtable is an important platform for Moleculin to convey the promise of Annamycin and its potential impact on AML treatment. The event will be streamed live, with a replay available on the company’s website for 90 days post-event.

Moleculin Biotech continues to pursue innovative solutions for difficult-to-treat conditions, leveraging its expanding portfolio to address unmet medical needs. The upcoming virtual AML Clinical Day underscores the company’s commitment to advancing clinical research and providing new hope for patients with acute myeloid leukemia.